Law360, New York (July 06, 2009, 12:00 AM ET) -- Genzyme Corp. has targeted Sandoz Inc, the generics arm of Novartis AG, in its latest effort to keep a generic version of Renagel off the market before the expiration of its patent for the well-known kidney treatment.
The Cambridge, Mass.-based drugmaker filed suit Thursday in the U.S. District Court for the District of Maryland over U.S. Patent Number 5,667,775, which covers both Renagel and Renvela, a second-generation form of the drug.
Renagel and Renvela are nonabsorbed, calcium-free, metal-free phosphate binders used to control serum phosphorus in...
Genzyme Takes On Sandoz Over Renagel ANDA
To view the full article, take a free trial now.
